Financiere des Professionnels Fonds d investissement inc. Purchases New Shares in Insulet Corporation $PODD

Key Points

• Financiere des Professionnels Fonds d'investissement inc. made a new investment of $543,000 by acquiring 1,727 shares of Insulet Corporation (PODD) during the 2nd quarter.
• Analysts have upgraded Insulet's stock to a consensus rating of "Moderate Buy", with a new price target set at $343.06.
• Recent insider trading includes SVP Laetitia Cousin selling 797 shares of Insulet at an average price of $348.81, reducing their ownership by 17%.

Financiere des Professionnels Fonds d investissement inc. bought a new stake in Insulet Corporation (NASDAQ:PODD - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,727 shares of the medical instruments supplier's stock, valued at approximately $543,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Zions Bancorporation National Association UT bought a new stake in Insulet in the first quarter worth about $26,000. Larson Financial Group LLC raised its position in Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after acquiring an additional 81 shares in the last quarter. SouthState Corp raised its position in Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 76 shares in the last quarter. Ramirez Asset Management Inc. bought a new stake in Insulet in the first quarter worth about $53,000. Finally, NewEdge Advisors LLC raised its position in Insulet by 44.8% in the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier's stock worth $54,000 after acquiring an additional 64 shares in the last quarter.

Insulet Stock Performance

Shares of Insulet stock traded down $2.67 during midday trading on Friday, hitting $330.84. The company had a trading volume of 1,028,492 shares, compared to its average volume of 567,226. The business's 50 day simple moving average is $315.14 and its two-hundred day simple moving average is $294.26. The stock has a market cap of $23.29 billion, a PE ratio of 100.56, a P/E/G ratio of 2.75 and a beta of 1.36. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. Insulet Corporation has a 1-year low of $225.37 and a 1-year high of $353.50.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping the consensus estimate of $0.92 by $0.25. The firm had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.Insulet's quarterly revenue was up 32.9% compared to the same quarter last year. During the same period last year, the business earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling at Insulet

In other news, SVP Prem Singh sold 687 shares of the company's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the company's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

Analyst Ratings Changes

PODD has been the topic of several research reports. Wall Street Zen upgraded shares of Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Morgan Stanley reaffirmed an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Insulet in a research note on Thursday, August 7th. Oppenheimer upped their price objective on shares of Insulet from $324.00 to $365.00 and gave the company an "outperform" rating in a research note on Monday, September 8th. Finally, Raymond James Financial reaffirmed an "outperform" rating and set a $360.00 price objective (up from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Sixteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Insulet has a consensus rating of "Moderate Buy" and an average price target of $343.06.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.